Evidence map›Paper›PMID 30573850›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.

Kenneth Tou En Chang, Amos Zhi En Tay, Chik Hong Kuick, Huiyi Chen, Elizabeth Algar, Nadine Taubenheim, Janine Campbell, Francoise Mechinaud, Martin Campbell, Leanne Super and 4 more

Abstract readCase ReportsMulticenter Study
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Basic Principles of Skin Biopsy Optimization in Dermatopathology.Dermatopathology (Basel, Switzerland) · 2026
    Review
  2. Review
  3. A frontal lobe mass in a 6-year-old girl.Brain pathology (Zurich, Switzerland) · 2026
    Article
  4. Article
  5. Review
  6. Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kenneth Tou En ChangDepartment of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore, Singapore. kenneth.chang.t.e@singhealth.com.sg.ORCID http://orcid.org/0000-0001-5244-4285
Amos Zhi En TayDepartment of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Chik Hong KuickDepartment of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Huiyi ChenDepartment of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore, Singapore.
Elizabeth AlgarCenter for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Nadine TaubenheimCenter for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Janine CampbellDepartment of Hematology, Royal Children's Hospital, Melbourne, VIC, Australia.
Francoise MechinaudChildren's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia.
Martin CampbellChildren's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia.
Leanne SuperChildren's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia.
Chavit ChantranuwatDepartment of Pathology, Faculty of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand.
S T YuenDepartment of Pathology, St. Paul's Hospital, Hong Kong, SAR, China.
John K C ChanDepartment of Pathology, Queen Elizabeth Hospital, Kowloon, Hong Kong, SAR, China.
Chung W ChowDepartment of Anatomical Pathology, Royal Children's Hospital, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2008, we presented three cases of ALK-positive histiocytosis as a novel systemic histiocytic proliferation of early infancy with hepatosplenomegaly and dramatic hematological disturbances. This series of 10 cases (including the original three cases) describes an expanded clinicopathological spectrum and the molecular findings of this histiocytic proliferation. Six patients had disseminated disease: five presented in early infancy with eventual disease resolution, and the sixth presented at 2 years of age and died of intestinal, bone marrow, and brain involvement. The other four patients had localized disease involving nasal skin, foot, breast, and intracranial cavernous sinus - the first three had no recurrence after surgical resection, while the cavernous sinus lesion showed complete resolution with crizotinib therapy. The lesional histiocytes were very large, with irregularly folded nuclei, fine chromatin, and abundant eosinophilic cytoplasm, sometimes with emperipolesis. There could be an increase in foamy histiocytes and Touton giant cells with time, resembling juvenile xanthogranuloma. Immunostaining showed that the histiocytes were positive for ALK, histiocytic markers (CD68, CD163) and variably S100, while being negative for CD1a, CD207, and BRAF-V600E. Next-generation sequencing-based anchored multiplex PCR (Archer® FusionPlex®) performed in six cases identified KIF5B-ALK gene fusion in five and COL1A2-ALK fusion in one. There was no correlation of gene fusion type with disease localization or dissemination. The clinicopathological spectrum of ALK-positive histiocytosis is broader than originally described, and this entity is characterized by frequent presence of KIF5B-ALK gene fusion. We recommend that every unusual histiocytic proliferative disorder, especially disseminated lesions, be tested for ALK expression because of the potential efficacy of ALK inhibitor therapy in unresectable or disseminated disease.

Indexed as

Cell ProliferationGene FusionAdolescentAdultChild, PreschoolCrizotinibFemaleGenetic Predisposition to DiseaseHistiocytesHistiocytosisHong KongHumansInfantInfant, NewbornMaleOncogene Proteins, FusionCrizotinibKIF5B-ALK fusion protein, humanOncogene Proteins, FusionProtein Kinase Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.